WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: 556354
CAS#: 1260094-44-7
Description: EC18 HCN inhibitor is a HCN channel inhibitor. EC18 acts as a potent HCN4 inhibitor in a human iPSC-derived sinus node model with proven HCN4 expression. EC18 is an attractive pharmacological tool, enabling HCN channel-modulation studies with some specificity for HCN4 (EC50 [HCN4] = 3.98 ± 1.16 µM) over HCN1 (EC50 = 21.00 ± 3.98 µM) and HCN2 (EC50 = 19.35 ± 4.48 µM). EC18 abolishes HCN4 triggered pace making in a human iPSC (hiPSC) pacemaker model.
Hodoodo Cat#: 556354
Name: EC18 HCN inhibitor
CAS#: 1260094-44-7
Chemical Formula: C29H40N2O5
Exact Mass: 496.29
Molecular Weight: 496.648
Elemental Analysis: C, 70.13; H, 8.12; N, 5.64; O, 16.11
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Related CAS #: 1260094-44-7
Synonym: EC18 HCN inhibitor; EC-18; EC 18; EC18;
IUPAC/Chemical Name: rel-3-[(1R,3R)-3-[[2-(3,4-Dimethoxyphenyl)ethyl]methylamino]cyclohexyl]-1,3,4,5-tetrahydro-7,8-dimethoxy-2H-3-benzazepin-2-one
InChi Key: IUAVZEYOWYFRAS-DNQXCXABSA-N
InChi Code: InChI=1S/C29H40N2O5/c1-30(13-11-20-9-10-25(33-2)26(15-20)34-3)23-7-6-8-24(19-23)31-14-12-21-16-27(35-4)28(36-5)17-22(21)18-29(31)32/h9-10,15-17,23-24H,6-8,11-14,18-19H2,1-5H3/t23-,24-/m1/s1
SMILES Code: O=C1N([C@H]2C[C@H](N(CCC3=CC=C(OC)C(OC)=C3)C)CCC2)CCC4=CC(OC)=C(OC)C=C4C1
Appearance: To be determined
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).
Solubility: To be determined
Shelf Life: >2 years if stored properly
Drug Formulation: To be determined
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info: HCN4 channels are considered to be a promising target for cardiac pathologies, epilepsy, and multiple sclerosis. However, there are no subtype-selective HCN channel blockers available, and only a few compounds are reported to display subtype preferences, one of which is EC18 (cis-1).
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 496.65 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
Patberg M, Oniani T, Disse P, Peischard S, Vinnenberg L, Zobeiri M, Romanelli MN, Epping L, Wiendl H, Meuth SG, Hundehege P, Seebohm G, Budde T, Junker A. Optimized synthesis and pharmacological evaluation of HCN channel inhibitor EC18. Arch Pharm (Weinheim). 2023 Jun;356(6):e2200665. doi: 10.1002/ardp.202200665. Epub 2023 Mar 22. PMID: 36949271.